1 – 15 of 23
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjogren's syndrome and rheumatoid arthritis
(
- Contribution to journal › Article
- 2013
-
Mark
COMP-C3b Complexes in Rheumatoid Arthritis with Severe Extraarticular Manifestations.
(
- Contribution to journal › Article
-
Mark
Reumatologisk forskning i Lund/Malmö
(
- Contribution to specialist publication or newspaper › Newspaper article
- 2012
-
Mark
Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
(
- Contribution to journal › Article
- 2011
-
Mark
Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis.
(
- Contribution to journal › Article
-
Mark
Ten years with biologics: to whom do data on effectiveness and safety apply?
(
- Contribution to journal › Article
-
Mark
Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Delays in assessment of patients with rheumatoid arthritis: variations across Europe
(
- Contribution to journal › Article
- 2010
-
Mark
Utility-based outcomes made easy: The number needed per QALY gained (NNQ). Observational cohort study from Southern Sweden of TNF blockade in inflammatory arthritis.
(
- Contribution to journal › Article
-
Mark
Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
(
- Contribution to journal › Article
- 2009
-
Mark
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor alpha Therapies Does the Risk Change With the Time Since Start of Treatment?
(
- Contribution to journal › Article
-
Mark
Differences in Longitudinal Disease and Treatment Characteristics of Patients with Rheumatoid Arthritis Replying and Not Replying to a Postal Questionnaire. Experience from a Biologics Register in Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Bone mineral density in the hand as a predictor for mortality in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
- 2008
-
Mark
Health utilities improvement during TNF blockade in chronic arthritis occurs early in the treatment course, results from an eight year observational study in southern Sweden
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.552-552(
- Contribution to journal › Published meeting abstract